Trials / Unknown
UnknownNCT04814069
A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To investigate whether concurrent Tislelizumab with postoperative chemoradiotherapy would have survival benefit in high Risk HNSCC Patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab | Tislelizumab 200mg q3w |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2023-04-01
- Completion
- 2023-12-31
- First posted
- 2021-03-24
- Last updated
- 2021-03-24
Source: ClinicalTrials.gov record NCT04814069. Inclusion in this directory is not an endorsement.